Covaxin Emergency Use Authorisation
- All
- News
- Videos
-
Covaxin Cleared For 6-12 Age Group, Corbevax For 5-12-Year-Olds
The Drugs Controller General of India (DCGI) today gave emergency use authorisation to Bharat Biotech's Covaxin for children between the age group of 6-12 amid an uptick in the Covid cases in schools.
-
Covishield, Covaxin Cleared For Market Approval By Expert Panel
An expert panel of India's central drug authority today recommended granting regular market approval to Covishield and Covaxin, which are currently only authorised for emergency use in the country, subject to certain conditions, official sources said
-
Recommendations On Covaxin Emergency Use For 2-18 Age Group Being Examined: Centre
The Covid Subject Expert Committee's recommendations on granting emergency use authorisation to Bharat Biotech's Covaxin for the 2-18 age group are being examined and additional information has been sought, Rajya Sabha was informed Tuesday.
-
WHO's Emergency Use Authorization For Covaxin "Expected Soon": Health Ministry
The Health Ministry on Friday hinted that the World Health Organization's (WHO) Emergency Use Authorization (EUA) for the COVID-19 vaccine, Covaxin, is expected soon.
-
WHO Emergency Approval For Covaxin Delayed Till October 5
World Health Organisation's (WHO) approval for the emergency use authorisation (EUA) to COVID-19 vaccine Covaxin, developed by the Hyderabad-based Bharat Biotech, is likely to be delayed till October 5.
-
After Halting Emergency Use, Brazil Shelves Import Permit Of Covaxin
After suspending the proposed clinical trials of Bharat Biotech's COVID-19 vaccine Covaxin and a request for Emergency Use Authorisation, Brazil now has suspended its decision to import four million doses of the jab into that country.
-
Brazil Scraps Covaxin Emergency Use Application Amid Political Row: Report
After suspending the proposed clinical trials of Bharat Bioetch's Covaxin, Brazil has now scrapped the Emergency Use Authorisation request made by the Indian firm for the vaccine.
-
We Respect US Decision On Covaxin's Emergency Use Authorisation: Centre
Centre said that the publication of Covaxin's phase 3 trial will be done sometime in 7-8 days.
-
US Delays Use Of India-Made COVID-19 Vaccine Covaxin. What It Recommended
In a setback to Bharat Biotech's COVID-19 vaccine Covaxin, the US Food and Drug Administration has "recommended" Ocugen Inc, the US partner of the Indian vaccine maker, to go for Biologics Licence Application (BLA) route with additional data.
-
Mexico Grants Authorisation For Emergency Use Of India's Covaxin Vaccine
The Mexico Federal Commission for the Protection Against Sanitary Risk (Cofepris) on Wednesday has granted authorization for the emergency use of India's first domestically-produced COVID-19 vaccine, Covaxin.
-
Covishield, Covaxin Safe, Side-Effects Negligible: NITI Aayog Member
Covishield and Covaxin, the two COVID-19 vaccines which have received Emergency Use Authorisation have been tested on thousands of people and side-effects are negligible, Dr VK Paul, Member (Health), NITI Aayog, said on Tuesday and noted that the two "are safest of the vaccines".
-
4 New Units To Manufacture 700 Million Vaccine Doses A Year: Bharat Biotech
Bharat Biotech, which has been accorded Emergency Use Authorisation from the drug regulator for its COVID-19 vaccine Covaxin, today said they are setting up four vaccine manufacturing facilities with a combined capacity of 700 million doses per year.
-
Covaxin Triggers Immune Response, No Adverse Effects In Phase 1 Trial
Covaxin, which is one of three coronavirus vaccine candidates being considered for emergency use authorisation in India, induced an immune response and registered no serious adverse events, interim findings of Phase I trials have revealed
-
Bharat Biotech Seeks Emergency Use Approval For Covaxin
Bharat Biotech, the Hyderabad-based pharmaceutical firm that has been developing coronavirus vaccine Covaxin, has applied to the central drug regulator seeking emergency use authorisation, sources said on Monday.
-
Covaxin Cleared For 6-12 Age Group, Corbevax For 5-12-Year-Olds
The Drugs Controller General of India (DCGI) today gave emergency use authorisation to Bharat Biotech's Covaxin for children between the age group of 6-12 amid an uptick in the Covid cases in schools.
-
Covishield, Covaxin Cleared For Market Approval By Expert Panel
An expert panel of India's central drug authority today recommended granting regular market approval to Covishield and Covaxin, which are currently only authorised for emergency use in the country, subject to certain conditions, official sources said
-
Recommendations On Covaxin Emergency Use For 2-18 Age Group Being Examined: Centre
The Covid Subject Expert Committee's recommendations on granting emergency use authorisation to Bharat Biotech's Covaxin for the 2-18 age group are being examined and additional information has been sought, Rajya Sabha was informed Tuesday.
-
WHO's Emergency Use Authorization For Covaxin "Expected Soon": Health Ministry
The Health Ministry on Friday hinted that the World Health Organization's (WHO) Emergency Use Authorization (EUA) for the COVID-19 vaccine, Covaxin, is expected soon.
-
WHO Emergency Approval For Covaxin Delayed Till October 5
World Health Organisation's (WHO) approval for the emergency use authorisation (EUA) to COVID-19 vaccine Covaxin, developed by the Hyderabad-based Bharat Biotech, is likely to be delayed till October 5.
-
After Halting Emergency Use, Brazil Shelves Import Permit Of Covaxin
After suspending the proposed clinical trials of Bharat Biotech's COVID-19 vaccine Covaxin and a request for Emergency Use Authorisation, Brazil now has suspended its decision to import four million doses of the jab into that country.
-
Brazil Scraps Covaxin Emergency Use Application Amid Political Row: Report
After suspending the proposed clinical trials of Bharat Bioetch's Covaxin, Brazil has now scrapped the Emergency Use Authorisation request made by the Indian firm for the vaccine.
-
We Respect US Decision On Covaxin's Emergency Use Authorisation: Centre
Centre said that the publication of Covaxin's phase 3 trial will be done sometime in 7-8 days.
-
US Delays Use Of India-Made COVID-19 Vaccine Covaxin. What It Recommended
In a setback to Bharat Biotech's COVID-19 vaccine Covaxin, the US Food and Drug Administration has "recommended" Ocugen Inc, the US partner of the Indian vaccine maker, to go for Biologics Licence Application (BLA) route with additional data.
-
Mexico Grants Authorisation For Emergency Use Of India's Covaxin Vaccine
The Mexico Federal Commission for the Protection Against Sanitary Risk (Cofepris) on Wednesday has granted authorization for the emergency use of India's first domestically-produced COVID-19 vaccine, Covaxin.
-
Covishield, Covaxin Safe, Side-Effects Negligible: NITI Aayog Member
Covishield and Covaxin, the two COVID-19 vaccines which have received Emergency Use Authorisation have been tested on thousands of people and side-effects are negligible, Dr VK Paul, Member (Health), NITI Aayog, said on Tuesday and noted that the two "are safest of the vaccines".
-
4 New Units To Manufacture 700 Million Vaccine Doses A Year: Bharat Biotech
Bharat Biotech, which has been accorded Emergency Use Authorisation from the drug regulator for its COVID-19 vaccine Covaxin, today said they are setting up four vaccine manufacturing facilities with a combined capacity of 700 million doses per year.
-
Covaxin Triggers Immune Response, No Adverse Effects In Phase 1 Trial
Covaxin, which is one of three coronavirus vaccine candidates being considered for emergency use authorisation in India, induced an immune response and registered no serious adverse events, interim findings of Phase I trials have revealed
-
Bharat Biotech Seeks Emergency Use Approval For Covaxin
Bharat Biotech, the Hyderabad-based pharmaceutical firm that has been developing coronavirus vaccine Covaxin, has applied to the central drug regulator seeking emergency use authorisation, sources said on Monday.
